A Closer Look into FDA-EUA Approved Diagnostic Techniques of Covid-19 | Zendy

Hyun-Ju Oh | Zendy; Hyunjeong Ahn | Zendy; Anubhav Tripathi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Closer Look into FDA-EUA Approved Diagnostic Techniques of Covid-19

Author(s) -

Hyun-Ju Oh,

Hyunjeong Ahn,

Anubhav Tripathi

Publication year - 2021

Publication title -

acs infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.324

H-Index - 39

ISSN - 2373-8227

DOI - 10.1021/acsinfecdis.1c00268

Subject(s) - covid-19 , food and drug administration , pandemic , medicine , diagnostic test , intensive care medicine , drug approval , risk analysis (engineering) , authorization , disease , virology , drug , computer science , infectious disease (medical specialty) , computer security , pathology , pharmacology , emergency medicine , outbreak

The 2019 coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 virus, caused a worldwide pandemic in 2020 and is the most urgent health issue worldwide. In this review, we highlight the details of Food and Drug Administration-Emergency Use Authorizations approved diagnostics kits, focusing on the similarities and differences. It is essential to understand the currently available options and the advantages and disadvantages each provides to select the appropriate products that maximize the testing efficiency. We believe this work will provide a holistic evaluation of the current COVID-19 diagnostic resources, including variations across the countries, and guide developing novel diagnostic techniques to improve and optimize the current testing options.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research